drugset / Trial / NCT03472833

High-dose Vitamin D3 in Pancreas Cancer

NCT03472833

Phase 3 Terminated 25 enrolled Medical University of Graz
RandomizedParallel-groupOpen-labelSupportive care

Summary

Different studies have shown that a deficiency in vitamin D (≤20ng/mL) results in higher rates in morbidity and mortality rates in cancer patients. Clinical studies investigated and demonstrated altered vitamin d tissue in pancreatic cancer. But there is no prospective study evaluating the beneficiary effects of oral supplementation of vitamin d in altered vitamin d tissue from pancreatic cancer. We want to examine the effect of a high dose vitamin D3 therapy vs. a standard base dose vitamin D3 therapy in pancreas cancer patients with a vitamin D deficiency. In case of benefit in our results we could implement vitamin D3 as a supportive standard therapy in pancreatic cancer patients.

Timeline

Start
2018-04-01
Primary completion
2021-04-20
Completion
2021-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 800 iu Oral
Subject Cholecalciferol Other / unclassified 4000 iu Oral